As many as 3,000 people transition from mild to moderate Alzheimer’s every day, which means the opportunity for these medicines to help these people has been severely diminished due to these unnecessary regulatory delays.
It’s a quintessential government outcome. A program intended to increase access to promising medical innovations is actually preventing Medicare beneficiaries from receiving FDA-approved treatments.
Medicare’s “coverage with evidence development” (CED) was never authorized by Congress. Instead, the Centers for Medicare & Medicaid Services created the program in 2005 by leveraging its authority to determine which medical technologies patients can access.
This is a tragedy playing out for people with Alzheimer’s disease.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
A Real and Present Threat to Alzheimer’s Patients
Wayne H Winegarden
As many as 3,000 people transition from mild to moderate Alzheimer’s every day, which means the opportunity for these medicines to help these people has been severely diminished due to these unnecessary regulatory delays.
It’s a quintessential government outcome. A program intended to increase access to promising medical innovations is actually preventing Medicare beneficiaries from receiving FDA-approved treatments.
Medicare’s “coverage with evidence development” (CED) was never authorized by Congress. Instead, the Centers for Medicare & Medicaid Services created the program in 2005 by leveraging its authority to determine which medical technologies patients can access.
This is a tragedy playing out for people with Alzheimer’s disease.
Read the op-ed in RealClearHealth:
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.